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Enrofloxacin, an antimicrobial agent used to treat bacterial diseases is well tolerated 
by cats at recommended dosage (5 mg/kg). To investigate the tolerance of high-dose 
of the Hipralona Enro-I
® (5% enrofloxacin solution) in cats, 28 urban cats (11 males 
and 17 females) between the weight of 1.3 and 2.4 kg were randomly assigned to a 
control group (n=4) and three treatment groups (n=8). Each treatment groups were 
injected low-dose enrofloxacin (5 mg/kg, IM), high-dose enrofloxacin (15 mg/kg, 
IM), and very high-dose enrofloxacin (25 mg/kg, IM) once daily for seven 
consecutive days. Blood samples were collected from jugular vein before injection 
of enrofloxacin in the hind limb muscles of cats as self-control, and at 3
rd, 7
th, 14
th, 
and 21
st days after first drug injection. Samples were tested for various 
hematological and serum biochemical parameters. The systemic tolerance during 
experiment was investigated via monitoring of behavior and general physical 
examination. Hematological and serum biochemical parameters were not 
significantly different between groups. In addition, there was no statistically 
difference between various sampling days for any treatment group in each 
parameter. Furthermore, there was no change in the behavior and the general health 
condition of cats in the control and the three experimental groups. As serum 
biochemical indications of hepatotoxication and nephrotoxication were not 
observed. It was concluded that muscular injection of enrofloxacin in doses up to 25 
mg/kg (5ED50) for seven consecutive days was tolerated by cats. 
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INTRODUCTION 
 
Fluroquinolones are a relatively new class of potent 
synthetic antimicrobial agents, with a long lasting 
bactericidal effect and a broad spectrum of antibacterial 
activity, including strains resistant to many other 
antibacterial agents (Guay, 1992; Choi et al., 2011). 
Several fluoroquinolones are used widely in human 
medicine. Enrofloxacin is the only member of the 
fluoroquinolone family in veterinary medicine. 
Enrofloxacin was synthesized in Bayer’s laboratories in 
the mid 1980’s and intended particularly for veterinary 
use. Good results of using enrofloxacin were reported in 
treating uncomplicated bacterial infections (Stanley and 
Pacchiana, 2008; Forster-van Hijfte et al., 2011) and in 
opportunistic mycobacterial infections in cats (Studdert 
and Hughes, 1992). Enro- floxacin has been used against 
gram-negative aerobes (E. coli, Proteus spp., Pasteurella 
multocida, Bordetella bronchiseptica, some Pseudomonas 
spp.);  Staphylococcus intermedius that causes bacterial 
pneumonia in cat; Haemobartonella felis as an agent of 
feline infectious anemia (Dowers et al., 2002). 
Administered at the originally recommended dosage 
of 2.5 mg/kg, PO, every 12 hours, the drug shown to be 
effective and well tolerated in cats. In 1997, the popular 
trend to administer bactericidal antibiotics on a once-daily 
basis to achieve higher peak plasma concentrations 
influenced the manufacturer of enrofloxacin to alter its 
dosing guidelines. Once-daily administration was 
associated with improved efficacy and less development 
of bacterial resistance (Turnidge, 1999). Although enro- 
floxacin typically has linear pharmacokinetics and serum 
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concentrations that can be correlated with bacterial 
effects, a variable dosing range of 5 to 20 mg/kg as a 
single or split dose was added to the enrofloxacin label. 
Because of the ease of injection a once-daily dose and 
the increasing resistance of isolates to other antimicro- 
bials, veterinarians commonly began administering large 
daily doses of enrofloxacin. Unfortunately, the new 
dosing guidelines were frequently exceeded, with doses 
being given often more than twice the maximum 
recommended dosage of 20 mg/kg/day (Gelatt et al., 
2001). Therefore, the aim of the present study was to 
investigate the tolerance of high-dose of enrofloxacin 
injection in cats.  
 
MATERIALS AND METHODS 
 
The experiments were performed on 28 urban cats, 
(11 males and 17 females) aged 2-5 years weighing 1.3-
2.4 kg. These cats were hunted by special safe traps from 
different parts of Shiraz. Cats were acclimated to 
laboratory housing for at least five weeks prior to the 
experiment. The cats were housed in individual cages with 
free access to drinking water and food. In the first week of 
the adaptation time, physical examination, CBC test, 
deworming, and ectoparasite treatment were performed to 
rule out other concurrent diseases and previous infections. 
Experimental procedures were according to National 
Institutes of Health and European Union guidelines for 
animal care. 
The cats were randomly allocated into three treatment 
(n=8) groups: low-dose enrofloxacin (5 mg/kg, =ED50) 
(Hipralona Enro-I
®, Hipra Co., Spain), high-dose enro- 
floxacin (15 mg/kg, =3ED50), and very high-dose 
enrofloxacin (25 mg/kg, =5ED50), and a control group 
(n=4, 0.5 ml distilled water as placebo) intramuscularly in 
the hind limb muscles, once daily for seven consecutive 
days. Blood samples were collected from jugular vein 
before injection of drug or placebo on day 0 as self-
control for each group. Further blood samples with or 
without anticoagulant were collected on days 3, 7, 14, and 
21 after first day of injection of drug or placebo. Samples 
were analyzed for hematological parameters (RBC counts, 
WBC counts, hemoglobin concentration, hematocrit, 
MCV, and MCHC) by using standard routine hema-
tological techniques (Weiss and Wardrop, 2010). Serum 
concentration of glucose was assayed by the O-toluidine 
method, total protein by the Biuret method, blood urea 
nitrogen (BUN) with the di-acetyl monoxime method, and 
creatinine with the modified Jaffe method. Serum enzyme 
activity of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) was evaluated by the colorimetric 
method. All blood samples were assayed by a technician 
who was blinded to the treatment groups. 
Amount of food and water consumption, body 
temperature, pulse, respiration, mucosa, general behavior 
(locomotion, coordination, special adequacy & purpose- 
fullness of locomotion, obstacle overcoming), defecation, 
micturition, skin and hair status were recorded by another
 
Table 1: Hematological parameters (Mean±SE) at sampling of pre-administration day and various days during and after injection of enrofloxacin for 
three groups of cats 
Sampling Days   Parameters 
0† 3  7 14  21 
PCV  (%)        
LD‡  37.13±1.6 36.75±1.7 37.00±1.6 36.63±1.7  37.25±1.8 
HD  39.88±2.0 40.13±1.8 39.63±1.9 39.37±1.9  39.25±1.8 
VHD  38.38±1.9 38.63±1.8 38.13±1.8 37.88±1.8  37.75±1.8 
Control  38.00±1.4 38.50±1.6 37.25±1.3 37.25±1.3  37.00±1.7 
P-value 0.73  0.59  0.72  0.71  0.83 
Hb  (g/dl)        
LD    8.98±0.4    8.99±0.4    8.99±0.4    8.99±0.4    8.99±0.4 
HD  10.05±0.7 10.05±0.7 10.05±0.7 10.05±0.7  10.06±0.7 
VHD    9.75±0.2    9.75±0.2    9.75±0.2    9.75±0.2    9.75±0.2 
Control  10.60±0.4 10.60±0.5 10.60±0.4 10.60±0.5  10.60±0.5 
P-value 0.23  0.24  0.24  0.24  0.23 
RBCs (10
6/µl)        
LD  10.26±0.2 10.25±0.2 10.25±0.2 10.26±0.2  10.26±0.2 
HD    9.69±0.4    9.70±0.4    9.66±0.4    9.69±0.4    9.69±0.4 
VHD    9.56±0.3    9.56±0.3    9.53±0.3    9.51±0.3    9.53±0.3 
Control    9.58±0.3    9.65±0.3    9.60±0.3    9.65±0.3    9.63±0.3 
P-value 0.34  0.39  0.34  0.33  0.38 
MCV  (fl)        
LD  35.88±1.6 35.63±1.7 35.88±1.7 35.38±1.7  36.13±1.7 
HD  40.88±2.0 41.13±2.0 41.00±2.0 40.50±2.0  40.38±1.8 
VHD  39.75±2.1 40.00±2.0 39.75±1.7 39.63±1.7  39.25±1.9 
Control  39.75±2.3 39.75±2.6 38.50±2.1 38.25±2.3  38.25±2.7 
P-value 0.29  0.21  0.24  0.22  0.43 
MCHC  (g/dl)        
LD  24.00±1.0 24.25±0.9 23.75±1.0 24.13±0.9  24.00±0.9 
HD  24.75±1.0 24.63±1.0 25.00±1.1 24.88±1.0  25.00±1.0 
VHD  25.00±0.9 25.00±0.9 25.38±0.9 25.50±0.9  25.63±0.9 
Control  27.25±0.5 26.75±0.3 28.00±0.4 28.00±0.6  28.25±0.3 
P-value 0.23  0.42  0.10  0.11  0.07 
WBC (10
3/µl)        
LD  1.21±0.2 1.17±0.2 1.16±0.2 1.13±0.1  1.09±0.1 
HD 1.98±0.3  1.66±0.2  1.51±0.2
  1.30±0.2 1.16±0.2 
VHD 1.23±0.3  1.11±0.2  0.82±0.1
  0.78±0.1 0.83±0.1 
Control  1.21±0.3 1.21±0.2 1.15±0.2 1.19±0.2  1.19±0.2 
P-value 0.08  0.24  0.07  0.10  0.35 
† After blood sampling enrofloxacin was intramuscularly injected once daily for seven consecutive days and the same, control group was injected by 
placebo (0.5 ml distilled water). ‡ LD low dose group (5 mg/kg), HD high dose group (15mg/kg), VHD very high dose group (25mg/kg). Pak Vet J, 2012, 32(1): 73-76. 
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Table 2: Biochemical parameters (Mean±SE) at sampling of pre-administration day and various days during and after injection of enrofloxacin for 
three groups of cats 
Sampling Days 
Parameters  0† 3  7  14  21 
ALT (U/L)           
LD‡ 48.94±2.3  52.19±4.3  45.88±2.7  45.82±3.3  48.07±3.6 
HD 43.19±2.4  46.50±3.7  43.57±2.8  46.00±4.1  43.32±2.6 
VHD 44.57±3.7  45.12±3.6  44.82±2.9  43.44±2.7  42.88±3.4 
Control  45.25±2.9  42.25±3.8    44.5±6.4  43.00±3.6  40.50±3.9 
P-value 0.51  0.41  0.96  0.90  0.49 
AST (U/L)           
LD 36.75±1.8  39.25±1.7  43.50±1.5  43.38±1.4  41.75±1.6 
HD 35.88±2.2  39.38±2.7  43.50±3.6  40.00±2.4  38.00±2.3 
VHD 37.13±1.7  45.13±2.7  46.63±1.9  38.13±2.2  35.63±2.2 
Control 35.75±3.1  36.25±2.5  35.75±1.6  37.00±0.8  38.00±1.1 
P-value 0.96  0.14  0.10  0.18  0.20 
Glucose (mg/dl)           
LD    96.79±4.5    96.96±4.5    97.01±4.5    96.97±4.5   97.05±4.6 
HD    88.16±6.7    88.39±6.7    88.50±6.7    88.47±6.6   88.61±6.7 
VHD 100.16±2.3  100.18±2.4  100.81±2.4  101.15±2.6  100.58±2.6 
Control    97.50±2.8    98.17±2.9    99.45±2.9    98.92±2.4  100.10±2.3 
P-value 0.31  0.32  0.28  0.27  0.29 
Total protein (g/dl)           
LD 7.73±0.3  7.17±0.2  7.08±0.2  7.00±0.2  6.93±0.2 
HD 7.70±0.2  7.45±0.3  7.37±0.3  7.29±0.3  7.24±0.3 
VHD 6.97±0.3  6.96±0.3  6.95±0.3  6.94±0.3  6.93±0.3 
Control 6.96±0.5  6.92±0.5  6.95±0.5  6.95±0.5  6.96±0.5 
P-value 0.13  0.60  0.72  0.80  0.82 
BUN (mg/dl) 
LD  32.19±3.8 32.51±3.9  30.90±3.9  32.32±3.8  32.44±3.9 
HD  36.15±9.4 36.83±8.9  36.92±9.2  36.87±8.7  36.95±9.1 
VHD  35.65±3.1 36.09±3.0  36.12±2.9  36.42±3.8  35.70±3.4 
Control  41.45±9.5 41.96±9.3  41.77±9.9  41.60±9.5  42.05±9.6 
P-value   0.37 0.33  0.26  0.36  0.33 
Creatinine (mg/dl) 
LD  1.42±0.5 1.45±0.5    1.47±0.5  1.47±0.4  1.40±0.5 
HD  1.37±0.4 1.37±0.5    1.40±0.3  1.42±0.5  1.43±0.4 
VHD  1.97±0.3  2.12±0.3    2.0±0.2  1.92±0.5    2.0±0.3 
Control  1.57±0.2 1.68±0.3  1.57±0.4  1.60±0.5  1.57±0.3 
P-value 0.19  0.10  0.16  0.44  0.22 
†After blood sampling enrofloxacin was intramuscularly injected once daily for seven consecutive days and the same, control group was injected by 
placebo (0.5 ml distilled water). ‡LD low dose group (5 mg/kg), HD high dose group (15mg/kg), VHD very high dose group (25mg/kg). 
 
author who was blinded to the treatment groups In 
addition, cats were daily assessed for immediate medical 
attention. The entire cats were adapted out to private 
homes at the end of the study. 
Parametric one-way ANOVA with Tukey test was 
used to investigate differences of hematological and 
biochemical parameters between groups (SPSS for 
Windows, version 11.5, SPSS Inc, Chicago, Illinois). P 
Value <0.05 was considered significant.  
 
RESULTS 
 
There was no change in the behavior and the general 
health condition of cats in the control and the three 
experimental groups. Statistical analysis indicated that 
there was no difference in PCV, Hb, RBC indices, and 
WBC count between the three treatment groups and the 
control group (P>0.05, Table 1). Furthermore, there was 
no difference in serum biochemical parameters (glucose, 
total protein, ALT, AST, BUN, and creatinine) between 
the three treatment groups and the control group (P>0.05, 
Table 2). In addition, there was no statistically difference 
between various sampling days for any treatment group in 
each parameter (P>0.05).  
 
DISCUSSION 
 
Results of the present study showed that there was no 
hematological and serum biochemical changes in cats 
treated with different doses of enrofloxacin. However, 
WBC count decreased between the expected normal 
variation in all groups during the study period, it was not 
considered as a treatment-related effect. Decreased WBC 
counts and PCV ratio were reported in humans receiving 
fluoroquinolones (Blum et al., 1994; Maguire et al., 
1994). However, these adverse effects were not observed 
in dogs receiving enrofloxacin (Traş et al., 2001). 
Injection of enrofloxacin did not change the serum 
glucose concentrations of cats during the study period. 
Consistent with our findings, using enrofloxacin did not 
reveal any significant effects on serum glucose in 
laboratory animals (Altreuther, 1987) and in dogs (Traş et 
al., 2001). Meanwhile, enrofloxacin at dosage of 5 and 10 
mg/kg, PO, q 12 h was administered to dogs for 1 day 
may result in underestimate urine glucose concentration 
(Rees and Boothe, 2004). Reported side effects of enro- 
floxacin in animals are lameness, acidosis, polydipsia and 
crystalluria (Orsini and Perkons, 1992; Boothe, 1994). 
However, the lack of changes in serum BUN & creatinene 
concentrations during the present study showed that 
enrofloxacin injection in cats had no nephrotoxic effect. 
Our results confirmed the lack of clinical 
manifestations of intolerance to enrofloxacin, reported by 
other authors (Kordick et al., 1997; Todorov, 2004). 
There were no symptoms of lameness, edema, painfulness 
and increased body temperature in all treated cats during Pak Vet J, 2012, 32(1): 73-76. 
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the period of study. Furthermore, the lack of changes in 
post treatment total protein values, AST and ALT 
activities vs the pretreatment values did not support the 
hepatotoxic effect of enrofloxacin (Greene et al., 2002). 
Enrofloxacin is reported to reduce specific liver enzymes 
(Vancutsem and Babish, 1996). However, a clinical study 
using enrofloxacin showed an increase of ALT and AST 
(Neer, 1988). In addition, Traş et al. (2001) showed that  
enrofloxacin injection at the recommended dose of 5 
mg/kg IM, once daily to healthy dogs for 14 days, causes 
a transient increases in AST and MCV levels. Similar 
effects are reported in humans receiving ciprofloxacin and 
norfloxacin (Davoren and Mainstone, 1993; Jones and 
Smith, 1997). Furthermore, enrofloxacin (20 mg/kg, PO, q 
24 h) caused a significant decrease in fibrinogen 
concentration in dogs (Webb et al., 2006). Meanwhile, 
serum total protein concentrations of the cats in the 
present study did not change after the injection of 
enrofloxacin with doses of 5, 15 and 25 mg/kg body 
weight, once daily for seven consecutive days. 
Unlike the data for ophthalmic disorders 
consequently to degenerative retinal changes in cats 
treated with enrofloxacin (Ford et al., 2007; Şaroglu and 
Erdikmen, 2008), the tested doses and regimen of 
application of Hipralona Enro-I
® did not result in 
clinically detectable changes in the vision of experimental 
animals (mydryasis, lack of coordinated and purposeful 
locomotion, obstacle overcoming). 
 
Conclusions 
Results of the present study indicated that the 
injection of enrofloxacin in doses up to 25 mg/kg   
(5ED50) for seven consecutive days was tolerated by cats 
& did not alter hematological & biochemical parameters.  
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